Polypeptide PT-1203 and application thereof in antitumor drugs

By designing the peptide PT-1203 and adopting microwave-promoted Fmoc protective solid-phase synthesis method, the targeting problem in existing ovarian cancer treatment methods is solved, efficient identification and killing of ovarian cancer cells is achieved, and a safe and effective way is provided. treatment plan.

CN119080884AActive Publication Date: 2024-12-06KETONOBEI BIOMEDICAL TECH (BEIJING) CO LTD
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
CN202411282923.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-13
Publication Date
2024-12-06
Estimated Expiration
2044-09-13

AI Technical Summary

Technical Problem

The existing ovarian cancer treatment methods have problems with early diagnosis, limitations of chemotherapy drugs, side effects of radiotherapy and insufficient targeted drugs, and new targeted treatment strategies are urgently needed.

Method used

Develop a peptide PT-1203, which can achieve high specific identification and targeted delivery of ovarian cancer cells by designing specific amino acid sequences, and prepare peptide-resin complexes by microwave-promoting Fmoc protection solid-phase synthesis method to improve drug stability Sexual and therapeutic effects.

Benefits of technology

The peptide PT-1203 has a good killing effect on ovarian cancer cells, is low in normal cytotoxicity and high in safety. It can achieve anti-tumor effects by promoting tumor cell apoptosis, providing a safer and more effective treatment option.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119080884A_ABST
    Figure CN119080884A_ABST
Patent Text Reader

Abstract

The invention relates to a novel polypeptide drug PT-1203 with antitumor activity, and belongs to the field of polypeptide drugs, and the amino acid sequence of the novel polypeptide drug PT-1203 is LVWKQSCSQTSK. The medicine has innovative significance in the field of polypeptide medicine research. By adopting a microwave-promoted Fmoc protection solid-phase synthesis method, the medicine can be rapidly and efficiently prepared, and the method not only improves the synthesis efficiency, but also ensures the stability of the synthesis process. Due to the excellent anti-tumor effect and high specificity, the medicine shows huge potential and application prospects in the field of anti-tumor treatment. In addition, the good practicability indicates that the medicine has wide application and remarkable market value in the aspect of preparing the anti-tumor medicine.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of polypeptide drugs, and particularly relates to the preparation of polypeptide PT-1203 and its application in anti-tumor drugs. Background Art

[0002] Ovarian cancer is one of the most common malignant tumors in the female reproductive system. Due to the difficulty in early diagnosis and limited treatment options in the late stage, the prognosis of patients is poor. At present, the treatment of ovarian cancer mainly relies on traditional methods such as surgery, chemotherapy and radiotherapy, but these methods have many shortcomings, such as low early diagnosis rate, limitations of chemotherapy drugs, side effects of radiotherapy, surgical risks, insufficient targeted drugs, etc., and new treatment strategies are urgently needed.

[0003] Peptide drugs can achieve highly specific recognition of tumor cell surface markers by designing specific amino acid sequences. Compared with traditional chemotherapy drugs, peptide drugs have lower toxic side effects and reduce damage to normal cells. Peptide drugs are easily enzymatically hydrolyzed in the body, reducing the potential toxicity caused by long-term accumulation. Easy to synthesize and modify: Peptide drugs can be efficiently synthesized by methods such as solid phase synthesis, and their pharmacokinetic properties can be improved by chemical modification. Peptide drugs can achieve targeted delivery to tumor tissues by coupling specific tumor homing peptides. Some peptide drugs have the potential to activate the body's immune system and enhance anti-tumor immune responses. Peptide drugs can inhibit tumor angiogenesis, cut off the nutrient supply of tumors, and inhibit tumor growth and metastasis. Peptides can form nanostructures through self-assembly as drug carriers to improve the stability of drug delivery systems.

[0004] In view of the shortcomings of existing technologies for the treatment of ovarian cancer, this patent aims to develop a new type of peptide drug for the targeted treatment of ovarian cancer to achieve precision treatment. The design of this patented drug fully utilizes the advantages of high specificity, low toxicity and side effects, and easy biodegradation of peptide drugs, while improving the stability and therapeutic effect of the drug through innovative synthesis and modification strategies. In addition, the present invention will also explore the potential of peptide drugs in terms of ovarian cancer cell toxicity, providing ovarian cancer patients with safer and more effective treatment options.

[0005] With the development of biotechnology, the application prospects of peptide drugs in the treatment of ovarian cancer are broad, and it is expected to provide patients with safer and more effective treatment options. In view of this, the present invention is proposed. Summary of the invention

[0006] The present invention aims to solve at least one of the technical problems existing in the above-mentioned prior art. To this end, the present invention proposes the use of a polypeptide PT-1203 in the preparation of an anti-tumor drug, wherein the polypeptide PT-1203 has low toxicity to normal cells but has a good killing effect on ovarian cancer cells.

[0007] The present invention provides a polypeptide PT-1203 with anti-tumor activity and use of a pharmaceutically acceptable salt thereof in the preparation of an anti-tumor drug, wherein the amino acid sequence of the polypeptide PT-1203 is: LVWKQSCSQTSK. The polypeptide PT-1203 contains 12 amino acid residues and has a molecular weight of 1393.70.

[0008] The polypeptide PT-1203 is a polypeptide chain independently developed and designed by the applicant. It is found that the polypeptide PT-1203 has mild toxicity to normal cells and can produce good killing effects on a variety of tumor cells. It can be used as an active ingredient to prepare anti-tumor drugs.

[0009] The polypeptide PT-1203 of the present invention has a short peptide chain and can be synthesized by solid phase synthesis, which has the characteristics of convenient and rapid synthesis.

[0010] The present invention provides a method for preparing the polypeptide PT-1203, which comprises preparing a polypeptide-resin complex by adopting a microwave-promoted Fmoc protection solid phase synthesis method, cleaving the polypeptide-resin complex with a cleavage agent to obtain a crude product, and purifying the crude product to obtain the polypeptide PT-1203.

[0011] The present invention provides an application of the polypeptide PT-1203 or the polypeptide PT-1203 obtained by the preparation method in the preparation of anti-tumor drugs.

[0012] The present invention provides use of a polypeptide PT-1203 or a pharmaceutically acceptable salt of the polypeptide PT-1203 obtained by the preparation method in the preparation of an anti-tumor drug.

[0013] Preferably, the anti-tumor drug is a drug that promotes tumor cell apoptosis. Experiments have shown that the polypeptide PT-1203 can achieve anti-tumor effects by promoting the apoptosis of tumor cells.

[0014] Preferably, the tumor is ovarian cancer.

[0015] The present invention provides a pharmaceutical composition, which comprises the polypeptide PT-1203 and / or a pharmaceutically acceptable salt of the polypeptide PT-1203.

[0016] Compared with the prior art, the beneficial effects of the present invention are as follows:

[0017] (1) The polypeptide PT-1203 of the present invention has low toxicity to normal cells and high safety.

[0018] (2) The polypeptide PT-1203 of the present invention has good inhibitory and killing effects on various tumor cells including ovarian cancer cells, and can be used to prepare corresponding anti-tumor drugs. BRIEF DESCRIPTION OF THE DRAWINGS

[0019] In order to more clearly illustrate the technical solutions in the embodiments of the present invention or the background technology, the drawings required for use in the embodiments of the present invention or the background technology will be described below.

[0020] Figure 1 A graph showing the test results of peptide PT-1203's toxicity to SKOV3 tumor cells;

[0021] Figure 2 A graph showing the test results of peptide PT-1203's toxicity to A2780 tumor cells;

[0022] Figure 3 A diagram showing the mass spectrometry detection results of the polypeptide PT-1203 obtained in Example 1 of the present invention;

[0023] Figure 4 The HPLC chromatogram of the polypeptide PT-1203 obtained in Example 1 of the present invention is shown. DETAILED DESCRIPTION

[0024] The present invention provides an anti-tumor polypeptide PT-1203, the amino acid sequence of which is shown as LVWKQSCSQTSK. In order to allow those skilled in the art to more clearly understand the technical solution of the present invention, the following examples are listed for illustration. It should be pointed out that the following examples do not limit the scope of protection claimed by the present invention.

[0025] In order to make the purpose, technical solution and advantages of the present invention more clearly understood, the present invention is further described in detail below in conjunction with the accompanying drawings and embodiments. It should be understood that the specific embodiments described herein are only used to explain the present invention and are not used to limit the present invention.

[0026] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.

[0027] Example 1: Preparation of polypeptide PT-1203

[0028] This embodiment provides a method for synthesizing a polypeptide PT-1203, whose amino acid sequence is: LVWKQSCSQTSK, which can be used to prepare anti-tumor drugs.

[0029] Main materials and instruments

[0030] Synthesis of polypeptide: The polypeptide PT-1203 used in the experiment was synthesized by our company's polypeptide synthesis laboratory using solid phase synthesis method with a purity of more than 95%.

[0031] The main experimental reagents (sources) disclosed in this disclosure are: Fmoc-Lys(Boc)-Wang resin (Gill Biochemical), Fmoc-Ser-OH (Gill Biochemical), Fmoc-Thr(tBu)-OH (Gill Biochemical), Fmoc-Leu-OH (Gill Biochemical), Fmoc-Val-OH (Gill Biochemical), Fmoc-Trp(Boc)-OH (Gill Biochemical), Fmoc-Gln(trt)-OH (Gill Biochemical), Fmoc- moc-Cys(trt)-OH (Gill Biochemical), Fmoc-Lys(Boc)-OH (Gill Biochemical), nitrogen, nitrogen-dimethylformamide (DMF) (Sinopharm), dichloromethane (Sinopharm), trifluoroacetic acid (McLean), triisopropylsilane (Aladdin), acetonitrile (Aladdin), nitrogen, nitrogen-diisopropylcarbodiimide (DIC) (Aladdin), ethyl 2-oxime cyanoacetate (McLean), 4-methylpiperidine (McLean), methyl tert-butyl ether (McLean).

[0032] The main experimental instruments (source) of this disclosure: Agilent HPLC-1260 series high performance liquid chromatograph (HPLC-1260 vial sampler, Quat Pump, MCT and DAD HS), Agilent HPLC / MSD iQ liquid chromatography tandem mass spectrometer (HPLC-1260 vial sampler, Quat Pump, MCT, DAD HS and / MSD iQ), CEM Liberty blue 2.0 fully automatic peptide synthesizer

[0033] The specific synthesis steps are as follows:

[0034] Synthesis of peptide resin: Weigh 0.1mmol of solid phase synthesis carrier Fmoc-Lys (Boc) -Wang resin and place it in a peptide synthesis solid phase reaction tube, add DMF (10mL) to swell the resin for 10 minutes, remove DMF by vacuum, add DMF (10mL) to wash the resin, and repeat washing twice. The peptide resin synthesis was completed using Liberty blue 2.0 fully automatic peptide synthesizer, in which amide bond condensation used 5 times excess of the corresponding Fmoc-protected amino acid, and the amino acid condensation was carried out using nitrogen, nitrogen-diisopropylcarbodiimide / 2-oxime ethyl cyanoacetate at 90°C microwave reaction for 2 minutes. Fmoc group deprotection was carried out using a DMF solution containing 20% ​​4-methylpiperidine at 90°C microwave reaction for 1 minute.

[0035] Cleavage of resin peptide: The resin peptide obtained in the above step was washed with DCM three times and then vacuum dried, and then 10 mL of cleavage solution (trifluoroacetic acid: triisopropylsilane: water = 90:5:5, v:v:v) was added and shaken for 2.5 hours at room temperature. After the reaction was completed, it was filtered, and the resin was washed with trifluoroacetic acid twice. After the filtrate was combined, a large amount of frozen methyl tert-butyl ether was added to precipitate solids, and the supernatant was removed after centrifugation to obtain the crude product of polypeptide PT-1203.

[0036] Purification of crude peptide: The crude peptide was dissolved in a mixed solvent containing 20% ​​acetonitrile / water, filtered through a 0.45 μm membrane, and separated using a high-pressure preparation system. The mobile phases were A (0.1% trifluoroacetic acid, 10% acetonitrile / water solution, v / v) and B (0.1% trifluoroacetic acid, 90% acetonitrile / water solution, v / v). During the purification process, the chromatograph detection wavelength was set to 220 nm and the flow rate was 20 mL / min. The product-related fractions were collected and lyophilized to obtain a pure polypeptide numbered PT-1203. The purity and molecular weight of the pure polypeptide were determined by analytical high performance liquid chromatography and liquid chromatography tandem mass spectrometry, where the purity = 98.31%, and the molecular weight was correct.

[0037] Example 2: Trypan blue was used to detect the killing efficiency of PT-1203 on SKOV3 tumor cells.

[0038] Main materials and instruments

[0039] The main experimental reagents (sources) disclosed in this invention are: SKOV3 (human ovarian cancer cells) purchased from Zhejiang Meisen Cell Technology Co., Ltd., and the required experimental materials are: DMEM basal culture medium; fetal bovine serum; ampicillin and streptomycin; DMSO; trypsin; PBS; trypan blue.

[0040] The main experimental instruments (source) used in this paper are: fully automatic cell analyzer (Shanghai Ruiyu Biotechnology Co., Ltd.), inverted microscope (OLYMPUS), BIOBASE carbon dioxide incubator (Jinan Xinbeisi Biotechnology Co., Ltd.)

[0041] Cell recovery: Take the cryopreserved tube of SKOV3 cell line out of the liquid nitrogen tank and place it in a 37℃ water bath to shake until it melts. Pipette the thawed cell line into a 15mL sterile centrifuge tube in a biosafety cabinet, centrifuge at 1000r / min for 5min, and remove the supernatant; add DMEM complete medium to SKOV3. Finally, transfer to a 25cm 2 The cells were cultured in sterile culture bottles at 5% CO2 and 37°C.

[0042] Cell passaging: Observe the cells under a microscope. When the cell morphology is normal and the growth density reaches about 90%, cell passaging is performed. First, take out the culture bottle containing the cells and place it in the clean bench, aspirate the original culture medium, wash the cells once with PBS buffer, aspirate the PBS and add 2mL of trypsin so that it can completely cover the bottom of the culture bottle, tighten the bottle cap and place it in a 37℃ incubator for digestion. After digestion, blow the cells off the bottle wall with fresh complete culture medium, then aspirate the cell suspension into a 15mL sterile centrifuge tube and centrifuge it at 1000r / min for 5min, remove the supernatant, add fresh complete culture medium to resuspend the cells and perform cell passaging at a ratio of 1:3.

[0043] Cell freezing: After centrifugation and removal of the supernatant according to the above cell passage process, add freezing solution (fetal bovine serum: DMSO = 9:1) to resuspend the cells, and add the suspension to 1.5 mL cell freezing tubes (each tube of cell suspension contains approximately 3×10 6 After labeling, they were cryopreserved by gradient cooling method.

[0044] In this experiment, SKOV3 tumor cells were treated with different concentrations of peptide PT-1203 for 24 hours, and then trypan blue in situ staining and counting were performed.

[0045] Trypan blue in situ staining: After the culture medium is discarded, trypan blue dye solution with a final concentration of 0.4% is added, incubated at room temperature for 8 minutes, the dye solution is discarded, rinsed once with PBS buffer, and observed and photographed under a microscope. The cells treated with different concentrations after staining are counted in situ, the number of cells stained with trypan blue is calculated, and the cell death rate is determined, thereby determining the killing efficiency of polypeptide PT-1203 on SKOV3 tumor cells.

[0046] Table 1 Killing efficiency of peptide PT-1203 on SKOV3 tumor cells

[0047] Dosing concentration 300μg / ml 200μg / ml 100μg / ml 50μg / ml Cell death rate 100.00% 83% 56% 20%

[0048] Combined with the trypan blue in situ staining experiment and the counting, it can be shown that the polypeptide PT-1203 has a killing efficiency on SKOV3 tumor cells.

[0049] Example 3: Trypan blue detection of PT-1203 killing efficiency against A2780 tumor cells

[0050] Main materials and instruments

[0051] The main experimental reagents (sources) disclosed in this invention are: A2780 (ovarian cancer cells) were purchased from Zhejiang Meisen Cell Technology Co., Ltd., and the required experimental materials are: DMEM basal culture medium; fetal bovine serum; ampicillin and streptomycin; DMSO; trypsin; PBS; trypan blue.

[0052] The main experimental instruments (source) used in this paper are: fully automatic cell analyzer (Shanghai Ruiyu Biotechnology Co., Ltd.), inverted microscope (OLYMPUS), BIOBASE carbon dioxide incubator (Jinan Xinbeisi Biotechnology Co., Ltd.)

[0053] Cell recovery: Take the A2780 cell line cryopreservation tube out of the liquid nitrogen tank and place it in a 37°C water bath to shake until it melts. Pipette the thawed cell line into a 15mL sterile centrifuge tube in a biosafety cabinet, centrifuge at 1000r / min for 5min, and remove the supernatant; add DMEM complete medium to A2780. Finally, transfer to a 25cm 2 The cells were cultured in sterile culture bottles at 5% CO2 and 37°C.

[0054] Cell passaging: Observe the cells under a microscope. When the cell morphology is normal and the growth density reaches about 90%, cell passaging is performed. First, take out the culture bottle containing the cells and place it in the clean bench, aspirate the original culture medium, wash the cells once with PBS buffer, aspirate the PBS and add 2mL of trypsin so that it can completely cover the bottom of the culture bottle, tighten the bottle cap and place it in a 37℃ incubator for digestion. After digestion, blow the cells off the bottle wall with fresh complete culture medium, then aspirate the cell suspension into a 15mL sterile centrifuge tube and centrifuge it at 1000r / min for 5min, remove the supernatant, add fresh complete culture medium to resuspend the cells and perform cell passaging at a ratio of 1:3.

[0055] Cell freezing: After centrifugation and removal of the supernatant according to the above cell passage process, add freezing solution (fetal bovine serum: DMSO = 9:1) to resuspend the cells, and add the suspension to 1.5 mL cell freezing tubes (each tube of cell suspension contains approximately 3×10 6 After labeling, they were cryopreserved by gradient cooling method.

[0056] In this experiment, A2780 tumor cells were treated with different concentrations of peptide PT-1203 for 24 hours, and then trypan blue in situ staining and counting were performed.

[0057] Trypan blue in situ staining: After the culture medium is discarded, trypan blue dye solution with a final concentration of 0.4% is added, incubated at room temperature for 8 minutes, the dye solution is discarded, rinsed once with PBS buffer, and observed and photographed under a microscope. The cells treated with different concentrations after staining are counted in situ, the number of cells stained with trypan blue is calculated, and the cell death rate is determined, thereby determining the killing efficiency of polypeptide PT-1203 on A2780 tumor cells.

[0058] Table 2 Killing efficiency of peptide PT-1203 on A2780 tumor cells

[0059] Dosing concentration 300μg / ml 200μg / ml 100μg / ml 50μg / ml Cell death rate 100% 100% 97.10% 98%

[0060] Combined with the trypan blue in situ staining experiment counting, it can be shown that the polypeptide PT-1203 exhibits significant killing efficiency against A2780 tumor cells.

Claims

1. A polypeptide PT-1203 having anti-tumor activity and its pharmaceutically acceptable salt in the preparation of anti-tumor drugs, It is characterized in that The amino acid sequence of the polypeptide PT-1203 is: LVWKQSCSQTSK.

2. A method for preparing the polypeptide compound as claimed in claim 1, Features: The polypeptide-resin complex was prepared by microwave-promoted Fmoc protection solid phase synthesis method, the polypeptide-resin complex was cleaved by a cleavage agent to obtain a crude product, and the crude product was purified to obtain polypeptide PT-1203.

3. Use of the polypeptide PT-1203 according to claim 1 or the polypeptide PT-1203 obtained by the preparation method according to claim 2 in the preparation of anti-tumor drugs.

4. Use of the polypeptide PT-1203 according to claim 1 or a pharmaceutically acceptable salt of the polypeptide PT-1203 obtained by the preparation method according to claim 2 in the preparation of anti-tumor drugs.

5. The use according to claim 1, It is characterized in that The anti-tumor drug is a drug that promotes tumor cell apoptosis.

6. The use according to any one of claims 1 or 3, 4, It is characterized in that The tumor is ovarian cancer.

7. A pharmaceutical composition, It is characterized in that The pharmaceutical composition comprises the polypeptide PT-1203 as claimed in claim 1 and / or a pharmaceutically acceptable salt of the polypeptide PT-1203.

Citation Information

Patent Citations

  • Application of polypeptide FL15 in preparation of antitumor drugs

    CN111729070A

  • Polypeptide PT-1031 and application thereof in antitumor drugs

    CN118530308A

  • Novel polypeptide for tumor targeting and application thereof

    WO2019154103A1

  • Synthetic peptide sp2 and use thereof

    WO2020093427A1